Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Desmoid tumour, drawn from the whole corpus: 6 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Ovarian toxicity of gamma-secretase inhibitors in young women: dose interruption and intermittent schedules are being explored.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Optimal treatment duration and whether responses persist after stopping nirogacestat.
Predicting which tumours will regress spontaneously (MRI signal and mutation type are candidate markers).
Head-to-head comparison of cryoablation versus systemic therapy for extra-abdominal disease.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 12 changes by month →When this page itself was last checked or edited.
Progressing desmoid tumours
First systemic therapy for desmoid tumours (DeFi)
Progressing desmoid tumours requiring systemic treatment
DeFi phase 3 (NEJM 2023); FDA approval 27 November 2023, the first for desmoid tumours.
PFS HR 0.